The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRB..L Share News (RB.)

  • There is currently no data for RB.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-UK doctors to trial ibuprofen in COVID-19 patients with breathing difficulties

Wed, 03rd Jun 2020 16:37

(Adds interview with researcher)

LONDON, June 3 (Reuters) - British doctors are trialling a
formulation of anti-inflammatory ibuprofen to see if it reduces
respiratory failure in patients with severe symptoms of
COVID-19.

The trial involves a particular formulation of ibuprofen,
which researchers said had been shown to be more effective than
standard ibuprofen for treating severe acute respiratory
distress syndrome (ARDS), a complication of COVID-19.

The formulation is already licensed for use in Britain for
other conditions.

"If successful, the global public health value of this trial
result would be immense given the low cost and availability of
this medicine," said Matthew Hotopf, director of NIHR Maudsley
Biomedical Research Centre.

The trial, known as "LIBERATE", will be a randomised study,
with recruitment of up to 230 patients expected over the coming
months.

It is being run by Guy's & St Thomas' NHS Foundation Trust
in London, King's College London (KCL) and pharmaceutical
organisation the SEEK Group.

In March, France's health minister said people should not
use anti-inflammatory drugs such as ibuprofen if they have
symptoms of COVID-19, the disease caused by the new coronavirus.

However, U.S., British and European Union drug regulators as
well as Reckitt Benckiser, which makes Nurofen, have all
said there is no evidence that ibuprofen makes COVID-19 worse.

Mitul Mehta, director of KCL's Centre for Innovative
Therapeutics, said that possible well-known gastric side effects
from ibuprofen meant that paracetamol was better to relieve
COVID-19 symptoms in its early stages.

But he added there was no evidence to back up the French
claims that ibuprofen worsens COVID-19 symptoms, saying the
formulation being used in the trial should lessen the possible
side effects.

"There's no way these early reports would've been talking
about this different formulation," Mehta told Reuters.

"The trial is the right forum in which to test the side
effects and to test the efficacy."

(Reporting by Alistair Smout; editing by Emelia
Sithole-Matarise and Ed Osmond)

More News
29 Jul 2020 13:29

Wednesday broker round-up

(Sharecast News) - Sanne: RBC Capital Markets reiterates sector performer with a target price of 600.0p.

Read more
29 Jul 2020 09:47

UK BROKER RATINGS SUMMARY: Berenberg Raises Carnival To Hold From Sell

UK BROKER RATINGS SUMMARY: Berenberg Raises Carnival To Hold From Sell

Read more
28 Jul 2020 17:01

LONDON MARKET CLOSE: FTSE 100 Ends Higher Thanks To Housebuilders

LONDON MARKET CLOSE: FTSE 100 Ends Higher Thanks To Housebuilders

Read more
28 Jul 2020 13:36

Reckitt seeks to cash in on cleaning brands with partnerships

By Siddharth CavaleJuly 28 (Reuters) - Exploiting the strength of Lysol and Dettol brands, Reckitt Benckiser is seeking bespoke supply and sanitation deals with travel companies and hotels as the coronavirus crisis makes hygiene a high priority.Br...

Read more
28 Jul 2020 11:04

UK TOP NEWS SUMMARY: Reckitt Gets Virus Boost For Cleaning Products

UK TOP NEWS SUMMARY: Reckitt Gets Virus Boost For Cleaning Products

Read more
28 Jul 2020 09:34

UPDATE 2-Defensives buoy UK stocks ahead of Fed outcome, U.S. stimulus decision

(For a live blog on European stocks, type LIVE/ in an Eikon news window)* Greggs shares slip despite jump in sales* Reckitt Benckiser, Card Factory rise after results* BHP, Rio biggest drag on FTSE 100* FTSE 100 up 0.4%, FTSE 250 adds 0.7% (Updates...

Read more
28 Jul 2020 08:41

LONDON MARKET OPEN: Stocks Start Higher As US Stimulus, Fed Meet Eyed

LONDON MARKET OPEN: Stocks Start Higher As US Stimulus, Fed Meet Eyed

Read more
28 Jul 2020 08:38

TOP NEWS: Reckitt Benckiser Interim Revenue Rises On Cleaning Products

TOP NEWS: Reckitt Benckiser Interim Revenue Rises On Cleaning Products

Read more
28 Jul 2020 08:02

LONDON BRIEFING: Reckitt Benckiser Rides Covid-19 "Tailwinds"

LONDON BRIEFING: Reckitt Benckiser Rides Covid-19 "Tailwinds"

Read more
28 Jul 2020 07:45

LONDON MARKET PRE-OPEN: Reckitt Hails Strong Half As Dettol Gets Boost

LONDON MARKET PRE-OPEN: Reckitt Hails Strong Half As Dettol Gets Boost

Read more
28 Jul 2020 07:34

UPDATE 2-Increased hygiene practices boost Reckitt Benckiser's first half

* Raises 2020 sales view to high single-digits* Lysol, Dettol are top performing brands* Shares down 1.6% after rising 25% this year (Adds details on brand sales, CEO quote, shares)By Siddharth CavaleJuly 28 (Reuters) - British consumer goods maker ...

Read more
28 Jul 2020 07:26

Cleaning product demand boosts Reckitt Benckiser H1

(Sharecast News) - Consumer goods giant Reckitt Benckiser reported a jump in first-half net revenue and profit on Tuesday thanks to a strong performance from its health and hygiene businesses as the Covid-19 pandemic boosted demand for cleaning and pain relief products.

Read more
27 Jul 2020 17:00

Delta teams up with Lysol to innovate on travel hygiene

CHICAGO, July 27 (Reuters) - Delta Air Lines said on Monday it is teaming up with Reckitt Benckiser Group Plc, the makers of Lysol, to research and develop new disinfecting solutions for high-traffic areas in airports and onboard, with a first fo...

Read more
24 Jul 2020 16:05

UPDATE 2-Indivior to pay $600 million to settle U.S. opioid treatment marketing claims

(Adds details from Justice Department)By Nate RaymondJuly 24 (Reuters) - Indivior Plc has agreed to pay $600 million and have a subsidiary plead guilty to a felony charge to resolve U.S. allegations that it engaged in an illegal scheme to boost pr...

Read more
24 Jul 2020 16:05

UPDATE 1-Indivior to resolve U.S. opioid treatment marketing claims for $600 million

(Adds further details on settlement, background on case)By Nate RaymondJuly 24 (Reuters) - Indivior Plc on Friday said it had agreed to pay $600 million and have a subsidiary plead guilty to a criminal charge to resolve U.S. allegations that it en...

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.